Dr Reddys gets USFDA EIR for Duvvada facilities

Published On 2022-02-21 10:07 GMT   |   Update On 2022-02-21 10:11 GMT
Advertisement

Hyderabad: Pharma major, Dr Reddy's Labs, today announced that the company has received the Establishment Inspection Report (EIR) from the U.S Food and Drug Administration (USFDA) for its formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, indicating closure of the inspection.

Establishment Inspection Report means the closure of inspection.

"Further to our intimation dated October 29, 2021, on the audit conducted by the USFDA at our formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the USFDA indicating closure of the inspection," the company stated in a BSE filing.

Advertisement

In October, Dr Reddys had got 8 observations from the USFDA after the conclusion of the audit at its formulations manufacturing facilities (FTO 7 & FTO 9) at Duwada, Visakhapatnam.

Read also: Dr Reddy's Labs Gets 8 USFDA Observations For Duwada Facilities

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddys, Binnopharm ink pact for 2 anti-bacterial brands for Russian region

In yet another news for the day, Dr. Reddy's Labs has joined hands with Binnopharm Group via its affiliate Joint Stock Company 'Alium' that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddy's in Russia, Uzbekistan and Belarus.

Read also: Dr Reddys, Binnopharm Ink Pact For 2 Anti-Bacterial Brands For Russian Region

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News